Non Hodgkin Lymphoma Clinical Trial

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Summary

The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Relapsed/refractory diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL)
Expression of CD30
Subjects must be 18 years or older (≥ 15 years for PMBL)

Exclusion Criteria:

Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy
Active, known, or suspected autoimmune disease

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

145

Study ID:

NCT02581631

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 27 Locations for this study

See Locations Near You

Local Institution - 0017
Birmingham Alabama, 35294, United States
University Of Miami Sylvester Comprehensive Cancer Center
Miami Florida, 33136, United States
Local Institution - 0012
Tampa Florida, 33612, United States
Winship Cancer Institute.
Atlanta Georgia, 30322, United States
University Of Chicago
Chicago Illinois, 60637, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Washington University School Of Medicine
Saint Louis Missouri, 63110, United States
Local Institution - 0003
New York New York, 10021, United States
Local Institution - 0010
New York New York, 10029, United States
University Of Rochester
Rochester New York, 14642, United States
Levine Cancer Institute
Charlotte North Carolina, 28204, United States
The Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States
Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States
Providence Portland Medical Center
Portland Oregon, 97213, United States
Bon Secours-St Francis Hosp
Greenville South Carolina, 29607, United States
University of Washington - Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
BC Cancer Agency - Vancouver Centre
Vancouver British Columbia, V5Z 4, Canada
Local Institution - 0011
Toronto Ontario, M5G 2, Canada
Jewish General Hospital
Montreal Quebec, H3T 1, Canada
Hopital Saint Louis
Paris , 75010, France
Local Institution - 0020
Pierre Benite Cedex , 69495, France
Local Institution - 0018
Bergamo , 0, Italy
Local Institution - 0024
Bologna , 40126, Italy
Istituto Clinico Humanitas
Rozzano (milano) , 20089, Italy
Local Institution - 0027
Hospitalet de Llobregat - Barcelona , 08908, Spain
Churchill Hospital
Oxford Oxfordshire, OX3 7, United Kingdom
Royal Marsden Hospital
Sutton Surrey, SM2 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

145

Study ID:

NCT02581631

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider